Oncotype DX Genomic Prostate Score predicts for long-term clinical outcomes

“This test requires just one millimeter of cancer on a biopsy on five consecutive slides,” says Eric A. Klein, MD.

JCO Precision Oncology recently published the paper, “GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality.” In this video, senior author Eric A. Klein, MD, discusses the background behind the study and what impresses him about the Oncotype DX Genomic Prostate Score. Klein is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic.

Related Videos
Dr. Sarah Psutka in an interview
Dr. Thomas Hutson in an interview at the ASCO annual meeting
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Dr. Michael Stifelman in an interview with Urology Times
© 2023 MJH Life Sciences

All rights reserved.